Medium and device for collecting, storing and transporting biological samples, as well as their use for the stabilization of extracellular nucleic acids

Medium, according to any of the previous claims, where the stabilizer may not necessarily include enzyme inhibitors—nucleases and/or proteases, including inhibitors of metabolic enzymes and inhibitors of phosphatase, which prevent the degradation of nucleic acids and ensure their stabilization, as well as inhibitors of apoptosis, including caspase inhibitors, including in combination with N,N-dialkylpropanamide, for example, with N,N-dimethylpropanamide (DMPA), or butanamide, which prevent cell apoptosis through a caspase-dependent pathway, and transcription inhibitors, which are designed to maintain the basic level of RNA expression at the time of blood sampling by inhibiting the synthesis of new RNA transcripts, including mRNA, microRNA, lncRNA, piRNA, YRNA, circRNA and other ncRNA:

• i) enzyme inhibitors can be selected from the groups of compounds, including but not limited to diethyl pyrocarbonate, ethanol, auryl tricarboxylic acid (ATA), glyceraldehydes, formamide, bentonite, ammonium sulfate, dithiothreitol (DTT), beta-mercaptoethanol, cysteine, dithioerythritol, tris(2-carboxyethyl)phosphine hydrochloride or combinations thereof;
• ii) inhibitors of metabolic enzymes can be selected from the groups of compounds, including but not limited to glyceraldehyde, dihydroxyacetone phosphate, glyceraldehyde-3-phosphate, 1,3-bisphosphoglycerate, 3-phosphoglycerate, 2 phosphoglycerate, phosphoenolpyruvate, pyruvate and glycerate dihydroxyacetate, potassium oxalate or combinations thereof;
• iii) protease inhibitors can be selected from the groups of compounds, including but not limited to antipain, chymostatin, elastatinal, phenylmethylsulfonyl fluoride (PMSF), APMSF, TLCK, TPCK, leupeptin, soybean trypsin inhibitor, indoleacetic acid (IAA), E64, pepstatin, 1,10-phenanthroline, phosphoramodone, amastatin, bestatin, diprotin A, diprotin B, alpha-2-macroglobulin, pancreatic protease inhibitor, ovostatin, cystatin, protease inhibitor, or combinations thereof;
• iv) phosphatase inhibitors can be selected from the groups of compounds, including but not limited to caliculin A, nodularin, NIPP-1, microcystin LR, tautomycin, okadaic (okadaic) acid, cantharidin, fostriyetsin, endothall, cyclosporin A, FK 506/immunophilin complexes, cypermethrin, deltamethrin, fenvalerate, defostatin, mpV (pic) DMHV, sodium orthovanadate, or combinations thereof;
• v) the content of enzyme inhibitors—nucleases and/or proteases, including inhibitors of metabolic enzymes and phosphatase inhibitors, can mainly range from 0% to 25.8% by weight of the entire formulation.

Medium, according to any of the previous claims, where the stabilizer may optionally contain the following compounds or combinations thereof at a concentration of 0% to 6.2%:

• i) proteins such as:
• biotin, albumins:
• egg, bovine, including bovine serum albumin—BSA, gelatin and similar compounds;
• ii) additional nucleic acid stabilizers such as:
• guanidine hydrochloride, polycations such as polyethyleneimine and similar compounds;
• iii) antioxidants/reductants such as Trolox, α-tocopherol, nicotinamide and similar compounds;
• iv) nucleic acid dyes such as:
• DAPI (diamidino-2-phenylindole), propidium iodide, fluorescein diacetate and similar compounds;
• v) antibiotics and other additional components, including but not limited to doxycycline, sulfasalazine, curcumin, 6-aminocaproic acid, minocycline, chitosan, phytic acid, β-sitosterol, c-AMP, polylysine, biochanin A, demeclocycline, chlortetracycline, oxytetracycline, cyclohexamide, rifampicin, soy milk, suramin, N-butyric acid, penicillamine, N-acetylcysteine, benzamidine, 2 aminoethylbenzylsulfonyl fluoride (AEBSF).